Breast-Specific Gamma Imaging (BSGI), an imaging technique that can aid in breast cancer diagnosis when a mammogram is inconclusive. This state-of-the-art technology can provide an extra measure of detection for cancerous cells in breast tissue.

BSGI is used as a less invasive "next step" following a mammogram that reveals an area of concern. BSGI is especially useful in early breast cancer detection and may help prevent the need for a biopsy. It is safe, effective, and comfortable for the patient and usually provides same-day results. BSGI is shown to be 96 percent accurate in determining if cancer is present or absent.

BSGI uses a specially developed camera that allows imaging with minimal breast compression. A small amount of a tracing agent–the same drug used safely in cardiac stress tests for more than 15 years–is injected into the patient's arm or foot. Because cancerous cells have a higher rate of metabolic activity, the tracing agent generally concentrates in cancer cells, if they are present, to a much greater degree than in normal cells. The tracing agent is detected by the imaging system examining the breast tissue; cancerous cells are seen as darker areas of enhancement. Patients are seated comfortably throughout the imaging process; each view takes between 5 and 10 minutes to acquire. Usually the same four views as a mammogram are obtained.

Monthly breast self-examinations and recommended mammograms remain the primary method of cancer detection, but BSGI is available when additional testing is necessary.

    BSGI is a strong diagnostic tool especially for patients who have:
  • dense breast tissue
  • suspicious areas on a mammogram.
  • lumps that can be felt but not seen with mammography or ultrasound.
  • breast augmentation that may interfere with a mammogram's reading or scarring from previous surgeries.

From surgical and treatment perspectives, BSGI also provides valuable information for determining extent of a primary lesion, detecting a secondary lesion and evaluating the axillary region for node status in breast cancer patients.

Back to Top

 
Contact | Directions | Site Map